公开(公告)号：US20220056136A1

公开(公告)日：2022-02-24

申请号：US17298741

申请日：2019-02-15

Applicant: ABL BIO INC. ,  I-MAB BIOPHARMA CO., LTD

Inventor： Eunyoung PARK ,  Yangsoon LEE ,  Hyejin CHUNG ,  Eunsil SUNG ,  Jiseon YOO ,  Minji PARK ,  Yong-Gyu SON ,  Hyoju CHOI ,  Eunjung KIM ,  Jaeho JUNG ,  Weon-Kyoo YOU ,  Sang Hoon LEE ,  Lei FANG ,  Wenqing JIANG

IPC: C07K16/28 ,  C07K16/46

Abstract: The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.

公开(公告)号：US20240101687A1

公开(公告)日：2024-03-28

申请号：US18480071

申请日：2023-10-03

Applicant: ABL Bio Inc.

Inventor： Jinhyung AHN ,  Sungwon AN ,  Dongin KIM ,  Eunsil SUNG ,  Jaehyun EOM ,  Sang Hoon Lee ,  Weonkyoo YOU ,  Juhee KIM ,  Kyungjin PARK ,  Hyejin CHUNG ,  Jinwon JUNG ,  Bora LEE ,  Byungje SUNG ,  Yeunju KIM ,  Yong-Gyu SON ,  Seawon AHN ,  Daehae SONG ,  Jiseon YOO ,  Youngdon PAK ,  Donghoon YEOM ,  Yoseob LEE ,  Jaeho JUNG

IPC: C07K16/28 ,  A61K47/68 ,  C07K16/18

CPC classification number: C07K16/2863 ,  A61K47/6845 ,  C07K16/18 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/567

Abstract: The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and an use of the bi-specific antibody for the prevention, treatment and/or diagnosis of synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates, and can allow the alpha-synuclein antibody or an antigen-binding fragment thereof to penetrate the blood brain barrier to exert its action in the brain, and extend the half-life to maintain the efficacy for a long time.

公开(公告)号：US20220348665A1

公开(公告)日：2022-11-03

申请号：US17616799

申请日：2020-06-15

Applicant: ABL Bio Inc.

Inventor： Sungwon AN ,  Jinhyung AHN ,  Byungje SUNG ,  Dongin KIM ,  Daehae SONG ,  Jaehyun EOM ,  Yong-Gyu SON ,  Kyungjin PARK ,  Juhee KIM ,  Jinwon JUNG ,  Bora LEE ,  Hyesu YUN

IPC: C07K16/28 ,  C07K16/18 ,  A61P25/28

Abstract: The present disclosure relates to a bispecific antibody that specifically binds to alpha-synuclein and IGF1R, and an use of the bispecific antibody for the prevention, treatment and/or diagnosis of synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates, and can allow the alpha-synuclein antibody or an antigen-binding fragment thereof to penetrate the blood brain barrier to exert its action in the brain, and extend the half-life to maintain the efficacy for a long time.

公开(公告)号：US20240383983A1

公开(公告)日：2024-11-21

申请号：US18684660

申请日：2021-08-18

Applicant: ABL BIO, INC.

Inventor： Kyungjin PARK ,  Yangsoon LEE ,  Saeyi LIM ,  Kyeongsu PARK ,  Minkyu SEON ,  Wonjun SON ,  Hyejin CHUNG ,  Yeryoung YONG ,  Yong-Gyu SON ,  Yeunju KIM ,  Youngdon PAK

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure provides an anti-B7-H4/anti-4-1BB bispecific antibody capable to effectively block the T-cell inhibitory effect of B7-H4 on the surface of tumor cells, and simultaneously activate 4-1BB on T-cells. The bispecific antibody may have high binding affinity to both of a B7-H4 protein (e.g., a human, monkey and mouse B7-H4 protein) and a 4-1BB protein (e.g., a human, monkey and mouse 4-1BB protein). The present disclosure also provides an anti-B7-H4 antibody specifically binds to B7-H4 protein.

公开(公告)号：US20230357412A1

公开(公告)日：2023-11-09

申请号：US18063550

申请日：2022-12-08

Applicant: ABL BIO INC.

Inventor： Sungwon AN ,  Jinhyung AHN ,  Byungje SUNG ,  Dongin KIM ,  Daehae SONG ,  Jaehyun EOM ,  Yong-Gyu SON ,  Juhee KIM ,  Kyungjin PARK ,  Jinwon JUNG ,  Bora LEE ,  Hyesu YUN

IPC: A61P25/28 ,  C07K16/18 ,  C07K16/28

CPC classification number: C07K16/2863 ,  A61P25/28 ,  C07K16/18 ,  A61K2039/505

Abstract: The present disclosure relates to a bispecific antibody that specifically binds to alpha-synuclein and IGF1R, and an use of the bispecific antibody for the prevention, treatment and / or diagnosis of synucleinopatheis associated with alpha-synuclein or alpha-synuclein aggregates, and can allow the alpha-synuclein antibody or an antigen-binding fragment thereof to penetrate the blood brain barrier to exert its action in the brain, and extend the half-life to maintain the efficacy for a long time.